Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study

por Furie, Richard A, Hough, Douglas R, Gaudy, Allison, Ye, Ying, Korish, Shimon, Delev, Nikolay, Weiswasser, Michael, Zhan, Xiaojiang, Schafer, Peter H, Werth, Victoria P
Publicado 2022

Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

por Schafer, Peter H., Kivitz, Alan J., Ma, Jianglin, Korish, Shimon, Sutherland, Donna, Li, Li, Azaryan, Ada, Kosek, Jolanta, Adams, Mary, Capone, Lori, Hur, Eun Mi, Hough, Douglas R., Ringheim, Garth E.
Publicado 2019

Biological impact of iberdomide in patients with active systemic lupus erythematosus

por Lipsky, Peter E, van Vollenhoven, Ronald, Dörner, Thomas, Werth, Victoria P, Merrill, Joan T, Furie, Richard, Petronijevic, Milan, Velasco Zamora, Benito, Majdan, Maria, Irazoque-Palazuelos, Fedra, Terbrueggen, Robert, Delev, Nikolay, Weiswasser, Michael, Korish, Shimon, Stern, Mark, Hersey, Sarah, Ye, Ying, Gaudy, Allison, Liu, Zhaohui, Gagnon, Robert, Tang, Shaojun, Schafer, Peter H
Publicado 2022

Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis

por FitzGerald, Oliver, Behrens, Frank, Barton, Anne, Bertheussen, Heidi, Boutouyrie-Dumont, Bruno, Coates, Laura, Davies, Owen, de Wit, Maarten, Fagni, Filippo, Goodyear, Carl S., Gurke, Robert, Hahnefeld, Lisa, Huppertz, Christine, Ioannidis, Vassilios, Ibberson, Mark, Katz, Arnon, Klippstein, Maximilian, Koehm, Michaela, Korish, Shimon, Mackay, Sina, Martin, David A., O’Sullivan, Denis, Patel, Khadijah, Rueping, Stefan, Schett, Georg, Scholich, Klaus, Schwenk, Jochen M., Siebert, Stefan, Simon, David, Vivekanantham, Arani, Pennington, Stephen R.
Publicado 2023